AI Model Compared With Imaging for Cervical Cancer Lymph Node Spread
Compares an AI model with imaging review in women with cervical cancer.
Plain-language title generated from the registry record
Registry title: A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 80 with stage I-III invasive cervical cancer who are having radical surgery with pelvic lymph node removal. It compares an AI model with imaging doctors in finding cancer spread to pelvic lymph nodes.
- Age
- 18 to 80 years
- Sex
- Women only
- Disease stage
- Invasive cervical cancer, stage I-III, any pathology type, treated with radical or modified radical surgery plus pelvic lymph node dissection
- Earlier treatment
- Must have had a pelvic MRI (plain or enhanced) before surgery. Must not have had or be having neoadjuvant chemotherapy or radiotherapy for this cancer.
Main reasons for not taking part
- Pregnant or breastfeeding, or abortion within 42 days
- Neoadjuvant chemotherapy or radiotherapy for this cervical cancer
- Another cancer within 5 years
- Another disease that may enlarge pelvic lymph nodes
- Pelvic MRI more than 1 month before surgery, or MRI images of poor quality
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06541288, who can take part
Where in China
- The Obstetrics and Gynecology Hospital of Fudan UniversityShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Obstetrics & Gynecology Hospital of Fudan University
- Trial code
- NCT06541288
- Record updated
- 7 August 2024
- Original description
The goal of this prospective cohort study is to learn whether artificial intelligence multimodal fusion prediction models are effective in diagnosing pelvic lymph node metastasis in cervical cancer. The main question it aims to answer is: can artificial intelligence multimodal fusion prediction models improve the accuracy of preoperative diagnosis of pelvic lymph node metastasis in cervical cancer? The researchers compared the AI multimodal fusion prediction model with traditional imaging physician assessments to see if the prediction model could yield more accurate lymph node metastasis determinations. Participants will undergo pelvic MRI after pathologically confirming a diagnosis of cervical cancer, and the results will be used to determine pelvic lymph node metastasis status by the predictive model and the imaging physician, respectively. Subsequent pathology results after surgical lymph node clearance will be used as the gold standard to determine the accuracy of the two preoperative lymph node diagnostic modalities.Read full original descriptionShow less
A Prospective Cohort Study Comparing Artificial Intelligence Multimodal Fusion Prediction Models With Conventional Imaging Assessment for the Diagnosis of Pelvic Lymph Node Metastasis in Cervical Cancer
The goal of this prospective cohort study is to learn whether artificial intelligence multimodal fusion prediction models are effective in diagnosing pelvic lymph node metastasis in cervical cancer. The main question it aims to answer is: can artificial intelligence multimodal fusion prediction models improve the accuracy of preoperative diagnosis of pelvic lymph node metastasis in cervical cancer? The researchers compared the AI multimodal fusion prediction model with traditional imaging physician assessments to see if the prediction model could yield more accurate lymph node metastasis determinations. Participants will undergo pelvic MRI after pathologically confirming a diagnosis of cervical cancer, and the results will be used to determine pelvic lymph node metastasis status by the predictive model and the imaging physician, respectively. Subsequent pathology results after surgical lymph node clearance will be used as the gold standard to determine the accuracy of the two preoperative lymph node diagnostic modalities.
Inclusion: patients with preoperative diagnosis of invasive cervical cancer stage I-III, with any type of pathology, and patients who underwent radical/modified radical cervical cancer surgery + pelvic lymph node dissection in our hospital or sub-center; Age ≥18 years and ≤80 years; patients who underwent preoperative pelvic MRI (plain/enhanced) imaging in our hospital or sub-centers.
Exclusion: patients whose preoperative pelvic MRI date is more than 1 month from the day of surgery; patients who are undergoing or have undergone preoperative neoadjuvant chemotherapy or radiotherapy for this cervical cancer; Patients with other malignant tumors within 5 years; Combination of other underlying diseases that may lead to enlarged pelvic lymph nodes; patients during pregnancy or lactation, patients with abortion within 42 days; poor quality imaging images that are unrecognizable.